AstraZeneca

AstraZeneca is a global biopharmaceutical company headquartered in Cambridge, UK (NYSE: AZN), formed in 1999 from the merger of Sweden's Astra and Britain's Zeneca. Its best-known medicines include the lung cancer drug Tagrisso, the immunotherapy Imfinzi and the diabetes and heart-failure drug Farxiga. In February 2026 it replaced its Nasdaq depositary shares with a direct New York Stock Exchange listing of its ordinary shares, keeping the ticker. It appears here not as an AI vendor but as a large pharmaceutical AI adopter, with one exception: Evinova, a separate health-tech business launched in November 2023, sells clinical trial software, including an AI-assisted study design tool, to other drug makers.

Its defining AI pattern is the acquirer, reached by way of a test drive. In July 2025 AstraZeneca signed a multi-year agreement with Modella AI, a Boston startup building pathology foundation models and AI agents. In January 2026 it bought the company outright, on undisclosed terms, to embed those models and agents inside its oncology research organization. Most drug makers rent AI through partnerships, but in this case the models and the people behind cancer biomarker work became something AstraZeneca owns.

Partnerships still carry most of the volume. In April 2025 Tempus AI said it would receive 200 million dollars in data licensing and model development fees to build an oncology foundation model shared by Tempus, AstraZeneca and Pathos. In October 2025 Algen Biotechnologies, a CRISPR gene-modulation spinout from UC Berkeley, signed an immunology deal worth up to 555 million dollars around its AlgenBrain target-discovery platform. In January 2026 it also became a founding participant, with Merck & Co. and Eli Lilly, in Illumina's Billion Cell Atlas, a genome-wide gene-editing dataset of a billion cells built to train biology models. In January 2026 AstraZeneca agreed to pay CSPC Pharmaceuticals 1.2 billion dollars upfront, with up to 3.5 billion dollars in development and regulatory milestones, for eight obesity and diabetes programmes that draw on CSPC's AI-driven peptide discovery platform; most of that money buys drug candidates rather than software. In May 2026 Immunai expanded its oncology work for a third time, eligible for up to 37.5 million dollars through 2027, and Owkin signed a three-year license for agents that answer competitive intelligence questions. Anthropic also features AstraZeneca as a customer of Claude for life sciences.

The strongest in-house example is Quantitative Continuous Scoring (QCS), a computational pathology method that measures a drug target on tumor cells from digitized slides. It sits inside Roche's TROP2 companion diagnostic for the cancer drug Datroway, which in April 2025 became the first computational pathology companion diagnostic to receive a Breakthrough Device Designation from the US Food and Drug Administration. A phase three trial that began in January 2026 enrolls lung cancer patients by that AI-scored biomarker. The company also says AI enables more than ninety percent of its small-molecule discovery pipeline.

The honest framing: AstraZeneca's value rests on its approved medicines and late-stage pipeline, and AI is a lever on top that shortens target discovery and sharpens patient selection. The Modella purchase and the QCS diagnostic are real commitments, while the pipeline percentage is the company's own measure of adoption, not a count of approved drugs AI produced. Among peers, Gilead procures specialists by partnership, Eli Lilly productized its own models through TuneLab and Moderna built hundreds of models in-house; AstraZeneca partners widely but is the one that bought an AI company outright.